{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-012435","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2026-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.803208+00:00","generated_at":"2026-05-15T06:16:51.661401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GeoVax reports 2025 net loss $21.5M; Phase 3 trial for mpox vaccine planned H2 2026","bullets":["Net loss $21.5M ($22.40/share) vs $25.0M ($120.46/share) in 2024; revenue $2.5M from BARDA contract.","Cash $3.1M at Dec 31, 2025; R&D expenses $18.1M (down from $23.7M); BARDA contract terminated Apr 2025.","GEO-MVA Phase 3 trial to start H2 2026; EMA supports streamlined development without Phase 1/2.","GEO-CM04S1 COVID vaccine Phase 2 data in 2026; Gedeptin oncology Phase 2 planned for 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-012435","json":"https://secwatch.observer/filing/0001437749-26-012435.json","markdown":"https://secwatch.observer/filing/0001437749-26-012435.md","text":"https://secwatch.observer/filing/0001437749-26-012435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/0001437749-26-012435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/govx20260415_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:16:51.661401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"724fa58b8fad5492edd4fdc0d4df02d524332d84","claim":"GeoVax Labs, Inc. reported the year ended December 31, 2025 results: revenue $2.5 million, net income $21.5 million, EPS $22.40 per share.","evidence_excerpt":"Net loss for the year ended December 31, 2025, was $21.5 million, or $22.40 per share, as compared to $25.0 million, or $120.46 per share, for the year ended December 31, 2024. Revenue : For the year ended December 31, 2025, the Company reported $2.5 million of government contract revenues associated with the BARDA/RRPV Project NextGen award, compared to $4.0 million during 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/0001437749-26-012435-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Revenue","value":"$2.5 million"},{"label":"Net income","value":"$21.5 million"},{"label":"EPS","value":"$22.40 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}